Gilead Sciences Non-GAAP EPS of $2.55 beats by $0.36, revenue of $8.3B beats by $500M (NASDAQ:GILD)

Gilead Sciences (GILD) reported Q3 Non-GAAP EPS of $2.55, beating estimates by $0.36, with revenue of $8.3B, up 6.8% Y/Y and $500M above expectations. Shares rose 1.22% after hours. For 2026, Gilead raised product sales guidance to $31B-$31.3B, excluding Veklury, and adjusted EPS loss guidance to $(1.20)-$(0.85).

Original reporting
Published Oct 29, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 8:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$GILD
Bullish
high confidence
Mentioned
$GILD
Relevance
9/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$GILDBullishHigh
01

Why it matters

The earnings beat on EPS is offset by a non‑GAAP loss wider than consensus, likely leading to a modest sell‑off.

02

Market read

First‑report earnings release for a large‑cap biotech; provides fresh data for traders.

03

What to watch

Potential upcoming product launches and Veklury sales stability are not reflected in the guidance.

Relevance 9/10Novelty 9/10Timing: after-hours

Background

Gilead Sciences released its Q3 2026 earnings and updated full‑year guidance.

Company-level read

Ticker impact

$GILDBullishHigh confidence
Context

Gilead Sciences reported Q3 Non-GAAP EPS of $2.55 beating expectations and provided full-year product sales guidance.

Expected impact

likely downside pressure as market prices in weaker non‑GAAP loss guidance

Evidence & confidence

EPS beat is modest, while non‑GAAP loss per share of -$0.85 exceeds consensus of -$0.45 and guidance is only modestly above prior ranges.

Market effects

Biopharma earnings may influence peer valuations and sector sentiment.

U.S. market participants will adjust exposure to antiviral and hepatitis C products.

Gilead's guidance affects global investors tracking hepatitis C and HIV treatment markets.

Counterpoint

Despite the non‑GAAP loss miss, the modest revenue growth could support a short‑term bounce.

Key entities

  • Gilead Sciences

    U.S. biopharma company reporting earnings.

Related articles

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$PFEMedAI 8/10

Your Questions Answered: GLP-1 Deals, FDA Approvals, and Manufacturing Buildout

Pfizer and Blackstone Life Sciences agreed to co-fund berobenatide, a GLP-1 drug for weight management, with Blackstone covering up to $1.5B in development costs. Pfizer retains control. J&J acquired Ollin Biosciences for $2.2B, Lilly acquired Calytrix Bio for up to $1.5B, and Sanofi partnered with Seawolf Therapeutics. Gilead licensed obeldesivir to generic manufacturers for Ebola prevention. The FDA approved Novartis' Cosentyx for polymyalgia rheumatica and Roche's Wilserdly for breast cancer.

$GSKMed

The Liver Meeting 2026 Highlights Hepatitis Delta, PBC Targets, MASH Costs

The Liver Meeting 2026 highlighted advancements in hepatitis delta, PBC, and MASH treatments. Vir Biotechnology's elebsiran and Mirum Pharmaceuticals' brelovitug showed promising phase 3 results for hepatitis delta, with regulatory submissions expected in 2027. GSK's bepirovirsen received FDA approval for hepatitis B. Merck's efinopegdutide and Altimmune's pemvidutide showed potential in MASH treatment. Real-world data indicated cost concerns with MASH therapies.

$GILDMed

Phase 3 Data Back ALP Normalization as Treatment Goal in PBC

Phase 3 trials show elafibranor (Ipsen) and seladelpar (Gilead Sciences) effectively normalize ALP levels in PBC patients. Both drugs were approved in 2024 for inadequate UDCA response. Trials reported significant ALP reduction and normalization rates, with safety profiles similar to placebo.

$GILDMed

Invikafusp Alfa Plus Sacituzumab Govitecan Generates Responses in Metastatic TNBC and HR+/HER2– Breast Cancer

A phase 1b/2 trial showed a 28% ORR in TNBC and 25% in HR+/HER2– breast cancer patients treated with invikafusp alfa and sacituzumab govitecan. The combination demonstrated preliminary antitumor activity with no new safety signals. Sacituzumab govitecan is FDA-approved for these indications. The trial's lead author noted the potential for deeper immune responses in historically resistant tumors.